Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)

Next Previous
Trial Profile

Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Teropavimab (Primary) ; Zinlirvimab (Primary) ; Antibodies
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms BEAT-2; BEAT-HIV-02

    • Most Recent Events

    • 06 Mar 2024 Results reporting a novel VL test based on capillary blood collection, comparing its specificity and sensitivity to conventional clinic-based plasma-based VL (pVL) presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 06 Mar 2024 Results evaluating the effect of a 26-week immunotherapy course with peg-IFN-alpha2b+bNAbs in the cytotoxic function and activation of natural killer (NK) cell subsets in persons with HIV infection (PWH) that participated in the BEAT 2 study presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 22 Feb 2023 Status changed from active, no longer recruiting to completed, as per results presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top